Could a brain booster stop schizophrenia before it starts?
NCT ID NCT05052853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug that boosts NMDA receptors can help people with early signs of schizophrenia. About 48 participants with prodromal symptoms will take the drug for 12 weeks. The goal is to see if it reduces symptom severity and delays progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRODROMAL SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Psychiatry, China Medical University Hospital
RECRUITINGTaichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain training from home: could a smartphone app sharpen thinking in early psychosis?
- Can a quick brain zap ease schizophrenia symptoms?
- Could a common antioxidant ease early psychosis symptoms?
- New Step-by-Step care model aims to halt psychosis in its tracks
- Can family therapy prevent psychosis in At-Risk youth?
- Brain training may boost social skills in at-risk teens